

Rationale Schmerztherapie – oder doch nicht?

Traitemment de la douleur – rationnel ou finalement pas?

Literatur / Références

1. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. *Eur J Pain* 2006;10:287–333.
2. Schussel K, Schulz M. Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals. *Die Pharmazie* 2006;61:878–86.
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. *The New England journal of medicine* 2000;343:1520–8, 2 p following 8.
4. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. *Arthritis and rheumatism* 2003;48:12–20.
5. Burmester G, Lanas A, Biasucci L, Hermann M, Lohmander S, Olivieri I, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. *Annals of the rheumatic diseases* 2011;70:818–22.
6. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. *Lancet* 2006;368:1771–81.
7. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. *Lancet* 2007;369:465–73.
8. Stichtenoth DO, Frolich JC. COX-2 and the kidneys. *Current pharmaceutical design* 2000;6:1737–53.
9. Schuijt MP, Huntjens-Fleuren HW, de Metz M, Vollaard EJ. The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. *British journal of pharmacology* 2009;157:931–4.
10. Hohlfeld T, Zimmermann N, Weber AA, Jessen G, Weber H, Schror K, et al. Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. *Journal of thrombosis and haemostasis: JTH* 2008;6:166–73.
11. Schweizerisches Kompendium der Medikamente. Available under www.kompendium.ch. 2012.
12. WHO's three-step pain "ladder" for cancer pain relief in palliative care. <http://www.who.int/cancer/palliative/painladder/en/>. Last accessed February 17, 2012. .
13. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. *Cochrane Database Syst Rev* 2006;CD004257.
14. Chou R, McDonagh MS, Nakamoto E, Griffin J. In: *Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review*. Rockville (MD); 2011.
15. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society* 2010;18:476–99.
16. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. *The FASEB journal: official publication of the Federation of American Societies for Experimental Biology* 2008;22:383–90.
17. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. *Circulation* 2006;113:1578–87.
18. Sudano I, Flammer AJ, Periat D, Enseleit F, Hermann M, Wolfrum M, et al. Acetaminophen increases blood pressure in patients with coronary artery disease. *Circulation* 2010;122:1789–96.
19. White WB, Campbell P. Blood pressure destabilization on nonsteroidal antiinflammatory agents: acetaminophen exposed? *Circulation* 2010;122:1779–81.
20. Watkins PB, Kaplanowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. *JAMA: the journal of the American Medical Association* 2006;296:87–93.
21. Doherty M, Hawkey C, Goulder M, Gibb I, Hill N, Aspley S, et al. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. *Annals of the rheumatic diseases* 2011;70:1534–41.
22. Brune K, Hinz B. Paracetamol, ibuprofen, or a combination of both drugs against knee pain: an excellent new randomised clinical trial answers old questions and suggests new therapeutic recommendations. *Annals of the rheumatic diseases* 2011;70:1521–2.

23. Hinz B, Brune K. Paracetamol and cyclooxygenase inhibition: is there a cause for concern? *Annals of the rheumatic diseases* 2012;71:20–5.
24. Neumann J. Advise against metamizole. *Deutsches Arzteblatt international* 2009;106:55–6; author reply 6.
25. Garcia S, Canoniero M, Lopes G, Soriano AO. Metamizole use among Hispanics in Miami: report of a survey conducted in a primary care setting. *Southern medical journal* 2006;99:924–6.
26. Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). *European journal of clinical pharmacology* 2002;58:265–74.
27. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. *JAMA: the journal of the American Medical Association* 1986;256:1749–57.
28. Ibanez L, Vidal X, Ballarin E, Laporte JR. Population-based drug-induced agranulocytosis. *Archives of internal medicine* 2005;165:869–74.
29. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. *Annals of internal medicine* 2007;146:657–65.
30. Metamizol: Weiter Berichte über Agranulozytosen.
http://www.aerzteblatt.de/studieren/nachrichten/47058/Metamizol_Weiter_Berichte_ueber_Agranulozytosen.htm. Aerzteblatt 2011.
31. Moorman J. Dipyrone (metamizole) use in the United States: a lethal tango? *Southern medical journal* 2006;99:916.
32. Baumgartner N, Luttres M. Metamizol: Gefahr erkannt – Gefahr gebannt? *Pharmajournal* 2011;06:5–7.
33. Kissel W, Jeger J. Somatoforme Schmerzen – Cave Opioide! *Swiss Medical Forum* 2012;12:149–52.
34. Aeschlimann A, Buettner UW, Desmeules JA, de Stoutz ND, Eychmüller S, Limacher F, et al. Empfehlungen zur Opioidtherapie chroinischer Schmerzen. Teil 1. *Swiss Medical Forum* 2005;5:1076–82.
35. Aeschlimann A, Buettner UW, Desmeules JA, de Stoutz ND, Eychmüller S, Limacher F, et al. Empfehlungen zur Opioidtherapie chroinischer Schmerzen. Teil 2. *Swiss Medical Forum* 2005;5:1107–13.
36. Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. *BMJ* 2001;322:1154–8.
37. Langford R, McKenna F, Ratcliffe S, Vojtassak J, Richarz U. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. *Arthritis and rheumatism* 2006;54:1829–37.
38. Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. *Archives of internal medicine* 2000;160:853–60.
39. Hale ME, Fleischmann R, Salzman R, Wild J, Iwan T, Swanton RE, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. *The Clinical journal of pain* 1999;15:179–83.
40. Caldwell JR, Hale ME, Boyd RE, Hague JM, Iwan T, Shi M, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. *The Journal of rheumatology* 1999;26:862–9.
41. Dunlop W, Uhl R, Khan I, Taylor A, Barton G. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate to severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. *Journal of medical economics* 2012.
42. Schutter U, Grunert S, Meyer C, Schmidt T, Nolte T. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/haloxone: a large observational study under conditions of daily practice. *Current medical research and opinion* 2010;26:1377–87.
43. Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. *Eur J Pain* 2009;13:56–64.